“Radiopharmaceuticals Market” study by “The Insight Partners” provides details about the market dynamics affecting the market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favorable competitive landscape and trends prevailing over the years.
The market is projected to reach US$ 13,818.17 million by 2028 from US$ 7,550.74 million in 2021; it is expected to grow at a CAGR of 9.0% from 2021 to 2028.
Companies Mentioned: Cardinal Health, GE Healthcare, Curium, Lantheus Medical Imaging, Bayer AG, Bracco Imaging, Eczacýbaþý-Monrol Nuclear Products, Nordion, Advanced Accelerator Applications, NTP Radioisotopes
Get Sample Copy of this Report: - https://www.theinsightpartners.com/sample/TIPRE00003751/
Based on type, the radiopharmaceuticals market is bifurcated into diagnostic nuclear medicine and therapeutic nuclear medicine. The diagnostic nuclear medicine segment is holding a larger share of the market and is expected to register a higher CAGR during the forecast period. The market growth for this segmented can be attributed to the availability of diagnostic devices and ease offered by these devices for the diagnosis of various disorders. Moreover, increasing incidence of cardiac diseases, cancer, and neurological disorders is expected to fuel the demand for better diagnosis of these disorders. Radiopharmaceuticals provide better diagnostic information about the functioning of a specific organ, as it uses radiation.
The radiopharmaceuticals market is segmented on the basis of type, product type, application, and end user. Based on type, the market is bifurcated into diagnostic nuclear medicine and therapeutic nuclear medicine. The diagnostic nuclear medicine is further bifurcated into SPECT (Single-Photon Emission Computed Tomography) applications and PET (Positron Emission Tomography) applications. The therapeutic nuclear medicine is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. Based on product type, the market is segmented into Technetium-99m, Thallium-201, Gallium-67, Iodine-131, Copper-64, and other. Based on application, the market is segmented into oncology, cardiology, neurology, and others. By end user, the market is segmented into hospitals, imaging centers, academic and research centers, and others.
The report facilitates in determining and interpreting the key market players, portfolios with necessary information such as company profiles, components and services offered, financial information of past few years, key developments in past few years, that helps in constructing strategies to gain competitive advantage in the long run. The report also analyzes factors affecting Tissue Plasminogen Activators market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend.
About The Insight Partners:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defence, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: [email protected]
#Radiopharmaceuticals, #Radiopharmaceuticals_Market, #Radiopharmaceuticals_Market_Analysis, #Radiopharmaceuticals_Market_Trend